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Defects in the regulation of apoptosis are one main cause of cancer development and may result
from overexpression of anti-apoptotic proteins such as the X-linked inhibitor of apoptosis protein
(XIAP). XIAP is frequently overexpressed in human leukemia and prostate and breast tumors. Inhi-
bition of apoptosis by XIAP is mainly coordinated through direct binding to the initiator caspase-9
via its baculovirus-IAP-repeat-3 (BIR3) domain. XIAP inhibits caspases directly making it to an
attractive target for anti-cancer therapy. In the search for novel, non-peptidic XIAP inhibitors in this
study we focused on the chemical constituents of sa¯ng bái pí (mulberry root bark). Most promising
candidates of this plant were tested biochemically in vitro by a ﬂuorescence polarization (FP) assay
and in vivo via protein fragment complementation analysis (PCA). We identiﬁed the Diels Alder
adduct Sanggenon G (SG1) as a novel, small-molecular weight inhibitor of XIAP. As shown by FP
and PCA analyses, SG1 binds speciﬁcally to the BIR3 domain of XIAP with a binding afﬁnity of
34.26 lM. Treatment of the transgenic leukemia cell line Molt3/XIAP with SG1 enhances caspase-8,
-3 and -9 cleavage, displaces caspase-9 from XIAP as determined by immunoprecipitation experiments
and sensitizes these cells to etoposide-induced apoptosis. SG1 not only sensitizes the XIAP-
overexpressing leukemia cell lineMolt3/XIAP to etoposide treatment but also different neuroblastoma
cell lines endogenously expressing high XIAP levels. Taken together, Sanggenon G (SG1) is a novel,
natural, non-peptidic, small-molecular inhibitor of XIAP that can serve as a starting point to develop
a new class of improved XIAP inhibitors.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Apoptosis or programmed cell death is a cellular process neces-
sary for successful embryonic development, the maintenance of
normal tissue homeostasis, the deletion of defective cells in the
body and suppression of oncogenesis.
In mammals apoptosis can mainly be initiated by two path-
ways: the extrinsic pathway which is triggered by the ligation of
death receptors on the cell surface and the intrinsic pathway which
is activated by intracellular damages and cellular stress [1] and is
regulated on the level of mitochondria by proteins of the BCL2 fam-
ily [2,3]. Both pathways converge to a common execution phase of
apoptosis that requires proteolytic activation of caspases-3 and/or
-7 from their inactive zymogens [4,5]. Apoptosis execution is
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inhibitor of apoptosis proteins (IAPs) which act as the key apopto-
sis regulators [6]. Therefore they are attractive molecular targets
for designing entirely new classes of anticancer drugs aiming to
overcome apoptosis resistance of cancer cells [7].
IAPs bind caspases and thereby interfere with apoptotic cell
death signaling via death receptors or intrinsic cell death path-
ways. They were originally discovered in baculoviruses as suppres-
sors of host cell apoptosis [8]. All IAP proteins share one to three
common structures of baculovirus-IAP-repeat (BIR) -domains that
allow them to bind and to inactivate caspases.
XIAP is the most potent inhibitor of apoptosis among the IAPs
[9]. Inhibition of apoptosis by XIAP is mainly coordinated through
direct binding to initiator caspase-9 via its BIR3-domain and by
binding the effector caspases-3 and -7 [10]. Negative regulators
of XIAP are SMAC/DIABLO and Omi, which are released from mito-
chondria in apoptotic cells, when the mitochondrial membrane
begins to collapse. SMAC/DIABLO is the most effective XIAP
inhibitor.
In several human malignancies an elevated expression of IAPs
has been reported [11–14]. Tamm et al. investigated the expression
of IAPs in 60 human tumor cell lines at mRNA and protein levels
and found higher expression of XIAP in most cancer cell lines ana-
lyzed [15]. Increased XIAP levels have been reported for esophageal
carcinoma, ovarian carcinoma, clear cell renal cancer and lym-
phoma [16–20]. In human prostate, non-small cell lung cancer cells
and hepatocarcinoma apoptosis resistance correlates with the
expression level of XIAP [21–24]. Several approaches to neutralize
XIAP and to re-sensitize tumor cells to chemotherapy have been
explored. In a ﬁrst approach antisense oligonucleotides [25] and
siRNAs [26–28], that are designed to decrease the mRNA and pro-
tein levels of XIAP, were used. Some of them are able to induce
spontaneous apoptosis and to enhance chemotherapeutics-
induced apoptosis in cancer cells [25,29]. The second and even
more promising approach is to sensitize cancer cells to chemother-
apeutic drugs by blocking XIAP’s anti-apoptotic activity by small
peptidic compounds that bind into the BIR3 domain, so called
SMAC-mimetics. These are usually small compounds derived from
the oligopeptide sequence of the SMAC N-terminus that binds into
XIAP. Most mimetics have a high afﬁnity but due to their peptidic
character they are also relatively instable and, as other peptide-
based inhibitors, do not efﬁciently enter cells [30–32]. An alterna-
tive method is to identify small non-peptidic molecules e.g. from
natural resources that mimic the SMAC interaction and can be used
as effective and affordable drugs in anticancer therapy.
By using a ﬂuorescence polarization (FP) -assay and based on
empirical knowledge we focused on the herbal remedy sa¯ng bái
pí (mulberry root bark form Morus alba L.). This plant material
is well known for its traditional use in Chinese medicine to treat
hypertension, upper respiratory diseases and edema and to pro-
mote urination [33]. Mulberry ﬂavonoids have been described
to possess anticancer activity [34]. Until now an anticancer activ-
ity has only been reported for multi-component mixtures, e.g.
aqueous Morus root bark extract induced apoptosis through inhi-
bition of microtubule assembly [35]. Recently, Choi et al. [36]
showed that inhibition of the YB-1 dependent MDR1 gene expres-
sion by the root extract decreased the viability of multidrug-resis-
tant MCF-7/Dox cells. However there is scarce information
available on chemically well-deﬁned constituents from Morus
root bark and their anticancer molecular mechanism. In this
study the molecular and physiological modes of action of most
promising constituents of this traditionally used herbal remedy
have been assessed in silico, in vitro and in vivo revealing sangge-
non G (SG1) as a non-peptidic, cell-permeable small inhibitor of
XIAP.2. Materials and methods
2.1. Plant material
The dried root bark of Morus sp. L., Moraceae, was purchased
from Plantasia (Import und Vertrieb asiatischer Heilkräuter,
Oberndorf, Austria). Its quality was macro- and microscopically
checked according to the monograph Sang-Bái-Pi of the Chinese
Pharmacopoeia. Voucher specimens (JR-20090112-A1) are depos-
ited in the Herbarium of the Department of Pharmacognosy, Insti-
tute of Pharmacy, University of Innsbruck, Austria.
2.2. Extraction and isolation
The dried root bark (1950 g) was crushed to coarse powder and
macerated exhaustively with methanol (7 l at room temperature,
three times for 7 days). Upon removal of the solvent under vac-
uum, the methanol crude extract yielded 168.6 g (termed MAC).
MAC was further defatted with petrol ether by means of liquid/
liquid partitions with methanol–water (1:1) and petrol ether, and
separated by silica gel column chromatography (CC) as reported
previously [37,38]. Fraction 4 (MAC-4, 15.3 g) enriched in Diels–
Alder adducts as monitored by thin layer chromatography (TLC)
was further separated by using different chromatographic meth-
ods. The isolation procedure was performed as described previ-
ously [37,38] and afforded pure compounds SG1–SG7. Their
structures have been determined by 1D and 2D NMR spectroscopy,
mass spectrometry and optical rotation and compared to previ-
ously obtained data [37–39]. Purity of the isolates was determined
by HPLC and 1H NMR and found to be >95%.
2.3. Cell lines, culture conditions and reagents
The acute lymphoblastic T-cell leukemia (T-ALL) lines Molt3
and Molt4, the rhabdomyosarcoma cell line OVCAR-4, the neuro-
blastoma cell lines SH-EP, IMR-32 and NxS2 as well as PhoenixTM
packaging cells for helper-free production of amphotropic retrovi-
ruses [40] were cultured in RPMI1640 (Lonza, Basel, Switzerland)
containing 10% fetal calf serum, 100 U/ml penicillin, 100 lg/ml
streptomycin and 2 mM L-glutamine (Gibco BRL, Paisley, UK) at
5% CO2 and 37 C in saturated humidity. HTB-77 cells were cul-
tured in McCoy’s 5a Medium Modiﬁed, supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100 lg/ml streptomycin (Gib-
co BRL, Paisley, UK). HEK293T cells for protein fragment comple-
mentation assays were cultured in DMEM medium (Gibco BRL,
Paisley, UK). All cultures were tested routinely for mycoplasma
contamination using the VenorR GeM-mycoplasma detection kit
(Minerva Biolabs, Germany). For each experiment, mid-log-phase
cultures were seeded in fresh medium. All cell lines used were
authenticated by ﬁngerprinting at the department of legal medi-
cine of the Medical University of Innsbruck.
2.4. Expression vectors
The vector pHED-XIAP-iresPuro was used for stable ectopic
gene expression and the plasmid pEF-XIAP-FLAG was used for
transient transfections. Both vectors have been described else-
where [41] and are a kind gift of John Silke from the Walter and
Eliza Hall Institute of Medical Research, Australia.
2.5. Production of retroviruses for infection of leukemia cells
Retrovirus supernatants were produced as described before
[42]. Brieﬂy, 6x105 PhoenixTM packaging cells were transfected
with 2 lg of retroviral vectors and 1 lg of a plasmid coding for
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48 h the virus-containing supernatants were ﬁltered through
0.22 lm syringe ﬁlters (Sartorius, Germany) and incubated with
the target cells for at least 6 h. Molt3 cells were infected with
either the empty pHED-iresPuro or the pHED-XIAP-iresPuro retro-
virus to generate Molt3/Ctr or Molt3/XIAP cells, respectively. The
cells were bulk-selected and the expression of XIAP was veriﬁed
by immunoblotting.
2.6. Immunoblotting and immunoprecipitation
For immunoblot analyses total protein was prepared from
6x106 cells resuspended in lysis buffer (50 mM HEPES-NaOH, 1%
Triton X-100, 150 mM NaCl, 2 mM EDTA, 10% glycerol) with prote-
ase and phosphatase inhibitors as described before [43,44]. Protein
concentration was measured using Bradford-Reagent (BioRad Lab-
oratories, Germany). Equal amounts of total protein (50 lg/lane)
were separated by SDS–PAGE.
For immunoprecipitation, 40 ll of anti-FLAG M2 magnetic
beads were added to 1.5 mg of total protein lysate containing a
protease inhibitor cocktail. Then SG1 or solvent was added to the
lysate and incubated for 3 h at room temperature. The tubes were
placed in a magnetic separator to isolate FLAG-tagged protein-bead
complexes. The beads were then washed three times in 1 ml wash
buffer, resuspended in SDS sample buffer and ﬁnally loaded on
SDS–PAGE. Equal amounts of total protein were present in the
supernatants (as demonstrated by the housekeeping control GAP-
DH) and equal amounts of XIAP were precipitated as proved by
FLAG-antibody staining. After gel separation proteins were trans-
ferred to nitrocellulose membranes (Schleicher & Schuell, Ger-
many) by a semi-dry blotting device (Hoefer TE70, Amersham
Biosciences). Membrane blocking was performed with PBS block-
ing buffer containing 0.1% Tween20 and 5% nonfat dry milk, incu-
bated with primary antibodies speciﬁc for human XIAP and
caspase-8 (BD Biosciences, Heidelberg, Germany), caspase-3 (Cell
signaling, Danvers, MA, USA), and caspase-9 (R&D Systems, Ger-
many), FLAG-M2 (Sigma–Aldrich, St. Louis, MO, USA), GAPDH
(Acris Antibodies, Herford, Germany) and a-tubulin (Oncogene
Research Products, La Jolla, CA), washed and incubated with anti-
mouse or anti-rabbit horseradish-peroxidase-conjugated second-
ary antibodies (GE Healthcare, Vienna, Austria). The blots were
developed by enhanced chemiluminescence (GE Healthcare,
Vienna, Austria) according to the manufacturer’s instructions and
analyzed with an AutoChemi detection system (UVP, Cambridge,
UK).
2.7. Apoptosis detection/ﬂow cytometry
Apoptosis was measured by staining the cells with propidium-
iodide (PI) and forward/sideward scatter analysis using a Cytomics
FC-500 (Beckman Coulter, Vienna, Austria). 2  105 cells were har-
vested and incubated in 500 ll hypotonic PI solution containing
0.1% Triton X-100 for 4–6 h at 4 C. Stained nuclei in the sub-G1
marker window were considered to represent apoptotic cells
[45]. For measurement of AnnexinV positive cells 5  105 cells
were harvested and stained with FITC-labeled AnnexinV (Alexis
Biochemicals, San Diego, CA, USA) in AnnexinV Binding Buffer
[46,47].
2.8. Production and puriﬁcation of recombinant BIR3 protein
DNA encoding BIR3 of human XIAP protein was ampliﬁed by
PCR and cloned into the pET30a(+) vector (Merck Millipore, Ger-
many) via the NdeI and SalI restriction sites. Protein expression
was performed in Escherichia coli BL21(DE3)pLysS (Merck Milli-
pore, Germany). E. coli carrying the pET30a(+)-XIAP-BIR3 plasmidwere cultured overnight in 25 ml of LB-medium with 50 lg/ml
kanamycin at 37 C. After 12–15 h the pre-culture was added to
500 ml of warm LB-medium and was expanded until the optical
density reached OD600 0.6–0.8. Protein production was induced
by 1 M IPTG. For protein isolation the bacterial pellet was resus-
pended in lysis buffer containing 50 mM NaH2PO4, 300 mM NaCl
and 2 mM imidazole supplemented with 0.1 mg/ml lysozyme,
1 mM PMSF and 1 tablet completeMini (Roche, Mannheim, Ger-
many) prior to use. After sonication the suspension was ﬁltered
through a 0.22 lm ﬁlter and was used for protein puriﬁcation on
an Äkta FPLC system (GE Healthcare, Vienna, Austria). Puriﬁcation
was done in two steps. Step 1: Afﬁnity chromatography with a
HisTrap HP column (GE Healthcare). After equilibration with wash
buffer (20 mM NaH2PO4, 500 mM NaCl and 2 mM imidazole) pro-
tein lysate was injected onto the column at a ﬂow rate of 0.5 ml
per minute. After reaching equilibrium the protein was eluted by
applying a gradient of elution buffer (20 mM NaH2PO4, 500 mM
NaCl and 500 mM imidazole) from 0–100% over 10 column vol-
umes. The elution process was monitored at UV 280 nm. The
protein was further puriﬁed in step 2 by size-exclusion chromatog-
raphy on a Superdex 75 10/300 GL column (GE Healthcare) in buf-
fer containing 20 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM
EDTA, 2 mM DTT, and 10% (w/v) glycerol [48]. Protein concentra-
tion was determined at 280 nm wavelength with a NanoDrop
ND-1000 UV–Vis spectrophotometer (PeqLabBiotechnologie,
Erlangen, Germany).
2.9. Fluorescence polarization (FP) -assay
To determine the binding of a substance to the BIR3-domain of
XIAP in vitro we established a FP-assay. Measurements were car-
ried out in black 96-well plates with ﬂat bottom (HVD Life Sci-
ences, Vienna, Austria) in a chameleon plate reader (Hidex,
Turku, Finland). 2 ll of substance were added to 103 ll/well
XIAP/ARPF Mix containing 20 nM ARPF-K(5-Fam)-NH2-peptide
(termed ARPF-FAM) and 720 nM BIR3 protein in assay buffer
(100 mM KH2PO4, pH 7.5; 100 lg/ml bovine serum albumin,
0.02% sodium azide). Positive (only assay buffer and FAM-peptide)
and negative (BIR3 protein and FAM-peptide) controls were ana-
lyzed on each plate. Millipolarization values (mP) were measured
at an excitation wavelength of 485 nm and an emission wave-
length of 530 nm. Speciﬁcity of compound binding was veriﬁed
using a second FP-assay that measures the interaction between
recombinant 14–3–3 sigma protein and R18 peptide [49,50].
2.10. Determination of the equilibrium dissociation constant (Kd), IC50
and binding afﬁnity (Ki)-values
The equilibrium dissociation constant was determined by using
the FP-assay as described above. Increasing concentrations of BIR3
protein from 0.1 nM to 5 lM were used. The equilibrium binding
isotherm was then calculated by plotting the FP read outs in mP
values as a function of the BIR3 protein concentration. The inhibi-
tion constant was calculated by nonlinear curve ﬁtting as the con-
centration of BIR3 protein at which 50% of the ligand is bound. Data
analysis was done with Prism 4.0 software (Graphpad Software,
San Diego, CA, USA).
The IC50 value of the substance SG1was also determined by FP-
analysis. Serial dilutions of the substance were added to the master
mix and polarization values were measured after 3 h of incubation.
FP readings were plotted as a function of the substance concentra-
tion and the IC50 values were determined by nonlinear least-
square analysis. The Ki values of the substance SG1 was calculated
using the online tool ‘‘The Ki calculator’’ (http://sw16.im.med.umi-
ch.edu/software/calc_ki/) based on the equation of Nikolovska-
Coleska [51].
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The biochemical activity of the substances in vivo was deter-
mined by PCA that measures cell-permeability and binding kinet-
ics of the substances in living cells. 6.5  105 HEK293T cells were
transfected with 2 lg plasmid-DNA using jetPrime (Polyplus-
transfection SA, Illkirch, France) in the following combinations:
pcDNA-BIR3-F1 and pcDNA-SMAC-F2 (1 lg each), pcDNA-Reg-F1
and pcDNA-Reg-F2 (1 lg each) and pRL-Renilla (2 lg) [52]. Cells
were treated 24 h after transfection with the substances in sub
toxic concentrations for 3 h. Samples were split in triplicates into
a white 96-well ﬂat bottom plate (HVD Life sciences, Vienna, Aus-
tria). Coelenteracine-h (Applichem, Darmstadt, Germany) was
added in a ﬁnal concentration of 0.25 ng/ll, and light emission
was measured by the chameleon plate reader (Hidex, Turku,
Finland).
2.12. Docking studies and structure–activity relationship analysis
(SAR)
Protein and ligand preparations were carried out using the soft-
ware tool MOE [53] and CORINA [54]. Docking studies were per-
formed with GOLD [55] version 5.2 using default parameters
(GOLDScore, 100% search efﬁciency). PDB entries 2OPY [56] was
selected as protein templates for human XIAP. The active site was
determined by selecting all residues within 8 Å from the outside
atoms of the co-crystallized smac mimicking peptide. Docking was
performed without any constraints and all compounds were mini-
mized using LigandScout’s general purpose MMFF94 implementa-
tion after docking. In order to get the most probable binding poses,
a 3D pharmacophore was developed with LigandScout, [57–59]
using the docking poses of the most active ligands synthesized in
this work. These 3D pharmacophores were then utilized to select
the docking poses that formed the basis for the described analysis.
LigandScout was also used for visualization, analysis and
illustrations.
2.13. Statistical analysis
For statistical analysis of experimental data the students t-test
was used in all cases except for the analysis of dose dependency
and the sensitization of neuroblastoma cells to chemotherapy-
induced apoptosis by SG1. In these cases an ANOVA with post
hoc Bonferroni-analysis was used. A 2-tailed P value 60.05 was
considered as signiﬁcant.
3. Results
3.1. In vitro screening for the identiﬁcation of natural substances that
speciﬁcally bind to the BIR3 domain of XIAP
For an automated medium throughput screening we estab-
lished a FP-assay platform to monitor the binding of the ﬂuoro-
phore-labeled peptide ARPF-FAM to the protein BIR3. The ARPF
peptide is derived from the AVPI peptide which is the main binding
sequence of the natural XIAP antagonist SMAC/DIABLO to BIR3. The
ARPF peptide shows, compared to AVPI a higher afﬁnity to the
XIAP-BIR3 domain which is achieved by replacement of the two
amino acids valine and isoleucine to arginine and phenylalanine
[60]. The binding of ARPF-FAM to BIR3 results in the decrease of
peptide rotation and hence in a measurable increase in polariza-
tion upon excitation with polarized light. By binding of a com-
pound with a higher afﬁnity to BIR3 the amount of unbound
highly rotating ARPF-FAM peptide increases resulting in a changed
polarization plane of the emitted light and in a reduction of mP
signal.In the search for small molecular natural compounds able to
interact with the BIR3 domain of XIAP, we screened in house avail-
able herbal extracts for the selection of promising starting material
for phytochemical investigation. The most pronounced reduction
of the mP value in the FP-screening was obtained for the methanol
crude extract of mulberry root bark (MAC). This result together
with data about the anticancer potential of this herbal remedy
[33–35] prompted us to further investigate its constituents. Frac-
tion MAC-4 obtained from column chromatography and enriched
in Diels–Alder adducts pointed to those ingredients in the multi-
component mixture most likely to be responsible for the selective
BIR3 binding afﬁnity (Fig. 1A). Compounds from MAC-4 have been
isolated and identiﬁed as sanggenon G (SG1), sanggenon D (SG2),
kuwanon L (SG3), sanggenon C (SG4), an equivalent mixture of
the isobars moracin O and P (SG5), sanggenon B (SG6) and sangge-
nol A (SG7). Apart from SG5 and SG7, all of these isolates bear the
characteristic feature of Diels–Alder adducts composed of a chal-
con and a ﬂavan moiety linked via a cyclohexene ring (Fig. 1B).
The in vitro screening of SG1–7 identiﬁed sanggenon G (SG1) and
kuwanon L (SG3) as those ingredients with the most pronounced
reduction of the mP value in the FP-screening (Fig. 1A and C). Com-
pounds SG1 and SG3 bind speciﬁcally to the BIR3 domain of XIAP
which is demonstrated by the reduction of the mP signal to 40%
of the control. Further SG1 did not affect protein–protein interac-
tion in a second FP-assay system that measures the binding of an
R18 peptide to recombinant 14–3–3 sigma protein. In addition also
the unspeciﬁc competitor R18 does not quench the mP signal in the
XIAP-BIR3 assay setup (Fig. 1C). To investigate the differences in
in vitro binding to XIAP-BIR3 in greater depth we analyzed the pro-
tein-inhibitor interactions at the level of BIR3 domain by docking
studies.
3.2. In silico validation of natural substances that speciﬁcally bind to
the BIR3 domain of XIAP
The crystal structure of XIAP reveals a BIR3 binding domain at
the surface of the enzyme [56]. PDB [61] entry 2OPY [56] was
selected as template and the protein structure was processed with
CCDC’s software GOLD [55] for docking experiments. After docking,
each docked conformation was geometrically optimized in the
binding site and prioritized using a 3D pharmacophore model
explaining the most plausible docking poses.
As a result, a comparable binding mode was identiﬁed for com-
pounds SG1 and SG3 (Fig. 1D). The cyclohexene ring of both com-
pounds was found in a central position, in the neighborhood of
Thr308. From there, the ligand can orient its peripheral moieties
in four directions towards different regions of the BIR3 binding
domain. The dihydroxybenzoyl groups of both compounds SG1
and SG3 point towards Tyr324 (Fig. 1D, pointing downwards). In
this region, the aromatic ring of each ligand is stabilized by a
hydrophobic contact with the Trp323, and a hydrogen bond can
be observed between the p-hydroxyl group of each ligand and
either the head of Tyr324 or the backbone carbonyl of Gly306.
The dihydroxyphenyl moiety of each ligand orients its hydroxyl
group towards the solvent, while the aromatic ring is stabilized
by a p–cation interaction with the positively charged head of
Lys297 (Fig. 1D, pointing to the left side). The remaining lipophilic
substitution of the central cyclohexene moiety forms hydrophobic
contact with the side chain of Thr308 (Pointing upward in Fig. 1D).
The forth moiety of ligands SG1 and SG3 (oriented to the right in
Fig. 1D) combine a 5,7-dihydroxychroman-4-one covalently linked
to a dihydroxyphenyl group. Although these moieties occur in
reverse order in SG1 and SG3, similar interactions are found with
the enzyme. In the ﬁrst ring, an H-bond donor in the ligand inter-
acts with the hydroxyl group of the Tyr 308 and/or the Asp309. In
the second ring, an H-bond with the side chains of Glu 314 and can
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referred to the web version of this article.)
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664 M.A. Seiter et al. / FEBS Open Bio 4 (2014) 659–671equally stabilize the elucidated binding mode. Additionally, a
p–cation interaction could be identiﬁed between the second
aromatic ring and Lys311 and Lys322. The reported interactions
that were shared in both binding modes were compiled in a 3D-
pharmacophore using LigandScout [57–59]. Interestingly, no docking
poses generated for all other compounds investigated in this study
could be matched to the above-described 3D model. This result is
in agreement with the low inhibitory potency against XIAP exper-
imentally determined for these molecules.
3.3. Compound SG1 but not SG3 interferes with binding of the SMAC/
DIABLO-derived AVPI peptide to the XIAP-BIR3 domain in living cells
Tomeasure binding dynamics of the SMAC/DIABLO-derived pep-
tide AVPI to the XIAP-BIR3 domain and possible effects of BIR3-tar-
geting compounds on this complex formation we set up an in vivo
analysis based on the protein fragment complementation principle
(Fig. 2A). For this assay theBIR3domainofXIAPand theAVPI peptide
of SMAC/DIABLO were fused each to a structural fragment of the
Renilla-luciferase. If the fragments of the luciferase get in closeprox-
imity a functional luciferase is formedand light is emitted. This com-
plex formation is reversible, which means that if a natural
compound is able to competeoff theAVPI-peptide the light emission
is reduced. SG1 signiﬁcantly reduced XIAP-BIR3/AVPI-SMAC com-
plex formation at 2.9 lM (P < 0.05) to about 56%, thereby prooﬁng
that this substance is membrane permeable and in vivo active, SG3
failed to reduce the bioluminescence signal speciﬁcally and signiﬁ-
cantly (Fig. 2B). SG1 and SG3 neither interact with the regulatory
subunits of the protein kinase A [52] nor with the Renilla protein
demonstrating that the SG1-mediated reduction of the XIAP-BIR3/
AVPI-SMAC complex formation is speciﬁc (Fig. 2B). The XIAP inhib-
itor embelin [7] was used as a control. Embelin diminishes the rela-
tive luminescence units (RLU) to 50% (Fig. 2C). Differences in the
chemical structure between the two compounds SG1 and SG3 point
to the different linkage between the ﬂavan- and chalcon moiety
(SG1, position 6 of the ﬂavonoids moiety; SG3, position 3’), but also
to the additional isoprenyl group in compoundSG1 (at the cyclohex-
ene ring). The latter difference distinctly confers to an increased
hydrophobicity (Fig. 1B) whichmay increase the ability of this com-
pound (in contrast to SG3) to transduce cytoplasm membranes.3.4. Biochemical characterization of SG1
As SG1 was able to inhibit the binding of the AVPI-peptide to
XIAP-BIR3 in living cells, we next analyzed the binding properties
of SG1 to XIAP-BIR3. To determine the IC50 for SG1 we ﬁrst mea-
sured the dissociation constant (Kd) for the protein/ligand pair
XIAP-BIR3/ARPF-FAM using a constant concentration of the probe
and titrating with the XIAP-BIR3 domain protein at increasing con-
centrations signiﬁcantly above the expected Kd of the protein-
probe pair. Fig. 2D (left graph) shows nonlinear least-square ﬁts
to a single-site binding model for a saturation experiment in which
the XIAP-BIR3 concentration varied from 0 to 15 lM at constant
ARPF-FAM concentration. The obtained Kd-value of binding
between the ARPF-FAM and the XIAP-BIR3 domain was deter-
mined to be 145 nM respective to our assay conditions. Of note
Nikolovska-Coleska et al. published for the same ligand–protein
pair using different assay conditions (differences in assay temper-
ature and recombinant BIR3 protein) a Kd-value of 38 nM.
For the determination of the IC50-value of substance SG1 a
competitive binding experiment with constant concentrations of
BIR3 protein and FAM-labeled probe was used. SG1 was then
titrated with increasing concentrations and the IC50 value was
determined from the graph to be 210 lM using nonlinear least-
square analysis (Fig. 2D, right graph).
The binding afﬁnity (Ki) -value of SG1 was calculated using the
equation of Nikolovska-Coleska [51] based upon the measured
IC50-value, the Kd-value of the probe and the XIAP-BIR3 complex
and the concentration of the protein and probe in the competition
assay. The Ki-value for SG1 at our assay conditions was 34.26 lM
(Fig. 2D). The Ki of embelin, at our conditions 22.3 lM, was
reported to be 0.4 lM using a slightly different BIR3 protein and
different measurement conditions [7].
3.5. SG1 treatment of Molt3/XIAP cells enhances caspase activation
In a next step we generated Molt3/XIAP leukemia cells that
ectopically express human XIAP to generate a model system for
XIAP-imposed drug resistance. For that purpose Molt3 cells were
infected with a retrovirus for constitutive expression of XIAP. Over-
expression of XIAP was veriﬁed by immunoblot (Fig. 3A). Molt3/
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Fig. 2. SG1 binds to the BIR3 domain of XIAP in vivo. (A) Schematic representation of the biosensor used in the protein fragment complementation assay. The BIR3 domain of
XIAP and the AVPI peptide of SMAC/DIABLO are fused to structural fragments of the Renilla-luciferase. If the fragments of the luciferase get in close proximity a functional
luciferase is formed and light is emitted under addition of the substrate. If a natural compound is able to compete off the AVPI peptide the light emission is reduced. (B)
Biological activity of SG1 in vivo is shown by PCA assay. SG1 displaces the AVPI-peptide from the BIR3 domain of XIAP in HEK293T cells thereby reducing luciferase activity.
The dissociation of the BIR3-SMAC complex by addition of SG1 (2.9 lM) results in a reduction of the Renilla-luminescence of 44%.SG1 does neither reduce Renilla-
luminescence of the control for unspeciﬁc protein interactions (REG1 + REG2) nor does it quench the Renilla-luminescence itself. Shown are means ± s.e.m. of three
independent experiments. Statistical analysis was done with the Student’s unpaired t-test, ⁄P < 0.05 compared to corresponding control. RLU (relative luminescence units). (C)
Biological activity of the control substance embelin in vivo is shown by PCA. Embelin (3.4 lM) has a similar effect on XIAP-BIR3-LucF1/AVPI-LucF2-luciferase activity as SG1.
Neither the Renilla-luminescence (right panel) nor the controls for unspeciﬁc protein interaction (middle panel) were affected by embelin. Shown are means ± s.e.m. of three
independent experiments. Statistical analysis was done with the Student’s unpaired t-test, ⁄P < 0.05 compared to corresponding control. (D) Biochemical characterization of
SG1: Binding isotherm of AbuRPF-K(5-Fam)-NH2 to the XIAP-BIR3 domain. The probe (24.8 nM) was incubated with increasing concentrations of the recombinant XIAP-BIR3
domain (0–15 lM). The Ki-value of SG1was calculated using the equation of Nikolovska-Coleska (51), based upon the measured IC50-value, the Kd-value of the probe and the
XIAP-BIR3 complex, and the concentration of protein and probe in the competition assay (720 nM BIR3, 24.8 nM probe).
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Fig. 3. Treatment of Molt3/XIAP cells with SG1 enhances caspase activation. (A) Molt3/XIAP cells are more resistant to etoposide-induced apoptosis than Molt3/Ctr cells.
Molt3/Ctr and Molt3/XIAP cells were treated with etoposide (100 ng/ml) for 72 h and then subjected to FACS analyses of PI-stained nuclei. Ectopic XIAP expression in Molt3/
XIAP cells is shown by immunoblot. GAPDH is used as loading control. (B) Treatment of XIAP overexpressing cells with substance SG1 leads to enhanced caspase-9 activity.
Molt3/Ctr and Molt3/XIAP cells were treated with SG1 (14.4 lM) alone and in combination with etoposide (130 nM) for 24 h. Caspase-9 activation was determined by
immunoblot. GAPDH served as loading control. The immunoblot was performed three times (independent experiments). Shown is one exemplary ﬁgure. (C) Molt3/Ctr and
Molt3/XIAP cells were incubated with 130 nM etoposide and 14.4 lM SG1 either alone or in combination for 24 h. Caspase-8 cleavage was then analyzed by immunoblot.
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was used as loading control. The immunoblot was performed three times (independent experiments). Shown is one exemplary ﬁgure. (E) HEK293T cells were transfected
with FLAG-tagged XIAP and treated with etoposide (130 nM), 14.4 lM SG1 or DMSO for 18 h and subjected to co-immunopuriﬁcation using anti-ﬂag beads.
Immunoprecipitates were analyzed for presence of caspase-9 by immunoblot. TP (total protein input), IP (immunoprecipitate), SN (supernatant). Areas containing the
expected bands were cropped and assembled to the ﬁnal ﬁgure. This applies for all immunoblots shown here.
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M.A. Seiter et al. / FEBS Open Bio 4 (2014) 659–671 667XIAP cells are less sensitive to etoposide-induced apoptosis
(100 ng/ml) compared to mock-infected Molt3/Ctr control cells as
measured by propidium iodide (PI) FACS analyses (Fig. 3A). For cas-
pase activation studies Molt3/Ctr and Molt3/XIAP cells were trea-
ted with etoposide (100 ng/ml) and then analyzed for caspase
activation by immunoblot. Addition of SG1 (14.4 lM) in combina-
tion with etoposide enhances caspase-9 activation compared to the
Molt3/Ctr and Molt3/XIAP cells treated with etoposide alone. Addi-
tion of the substance alone does not enhance caspase-9 activation
(Fig. 3B). Treatment of Molt3/XIAP cells with SG1 and etoposide
further leads to enhanced caspase-8 cleavage compared to
Molt3/Ctr and Molt3/XIAP cells treated with etoposide alone and
reaches nearly the same extend than in Molt3/Ctr cells treated
with both substances (Fig. 3C). Enhanced caspase-3 cleavage can
also be monitored in Molt3/XIAP cells that have been treated with
SG1 and etoposide compared to the Molt3/XIAP cells treated only
with etoposide. Nevertheless caspase-3 cleavage does not reach
the same amount as in Molt3/Ctr cells (Fig. 3D).
3.6. Treatment of Molt3/XIAP cells with SG1 reactivates caspase-9 by
releasing it from XIAP
In XIAP overexpressing cell lines apoptosis execution is often
blocked by the XIAP-mediated inhibition of caspase-9. To testB 
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Fig. 4. Treatment of Molt3/XIAP cells with SG1 inhibits cell growth and enhances etopos
growth of the XIAP-overexpressing cell line Molt3/XIAP in combination with etoposide
combination with etoposide (130 nM) for the indicated time points. Cells were counte
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compound SG1 sensitizes Molt3/XIAP cells to etoposide-induced apoptosis. Molt3/Ctr an
etoposide (130 nM) for 72 h and were then subjected to FACS analyses of PI-stained nuc
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experiments. Statistical analysis was done with the Student’s unpaired t-test, ⁄P < 0.05
Molt3/XIAP cells were treated with increasing concentrations of SG1 (8.2–14.4 lM) alone
by AnnexinV staining. Shown are means ± s.e.m. of three independent experiments.whether the apoptosis inducing potential of SG1 can be ascribed
to the competition of caspase-9 for the caspase-9 binding site of
XIAP, we performed a co-immunoprecipitation experiment. There-
fore we prepared cell lysates from HEK293T cells transfected with
an expression vector for FLAG-tagged XIAP, which were cultured in
presence/absence of etoposide for 16 h to initialize a mitochondrial
death signal. The lysates were split and incubated with either SG1
or solvent and to directly assess whether SG1 can displace caspase-
9 from XIAP. As shown in Fig. 3E, an increased amount of caspase-9
can be co-precipitated in etoposide treated cells compared to con-
trols. SG1 (14.4 lM) signiﬁcantly reduces the amount of co-precip-
itated caspase-9. This indicates that SG1 is able to release caspase-
9 from its antagonist XIAP and thereby SG1 sensitizes to apoptosis
triggered via caspase-9.
3.7. SG1-treatment of XIAP-overexpressing Molt3 cells inhibits cell
growth and enhances etoposide-induced apoptosis
To further investigate the physiological effects of SG1 we trea-
ted Molt3/XIAP cells with etoposide and 14.4 lM SG1 alone and
in combination and analyzed cell growth over 96 h. As shown in
Fig. 4A the combination treatment leads to a signiﬁcant reduction
of cell growth in Molt3/XIAP cells compared to the treatment with
etoposide alone. In Molt3/Ctr cells no further growth reduction0
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ide-induced apoptosis in a dose-dependent manner. (A) The compound SG1 inhibits
. Molt3/Ctr and Molt3/XIAP cells were incubated with SG1 (14.4 lM) alone and in
d with a Casy cell counter (Roche Diagnostics, Mannheim, Germany). Shown are
e Student’s unpaired t-test, ⁄P < 0.05 compared to corresponding controls. (B) The
d Molt3/XIAP cells were treated with SG1 (14.4 lM) alone and in combination with
lei. For analysis of apoptotic cells by AnnexinV staining, cells were incubated with
alyzed for AnnexinV positive cells. Shown are means ± s.e.m. of three independent
compared to corresponding control. (C) For dose–response curves Molt3/Ctr and
and in combination with 130 nM etoposide for 24 h. Apoptotic cells were analyzed
668 M.A. Seiter et al. / FEBS Open Bio 4 (2014) 659–671could be achieved due to their lower XIAP levels resulting in a
decreased resistance to etoposide-induced apoptosis. SG1 alone
leads to a lower reduction of cell growth in both cell lines. To
determine the impact of SG1 on apoptosis induction we treated
Molt3/Ctr and Molt3/XIAP cells with SG1 (14.4 lM) alone and in
combination with etoposide (100 ng/ml) and subjected them to
ﬂow cytometric measurements of apoptotic cells either by Annex-
inV staining or by analysis of propidium-iodide stained nuclei
(Fig. 4B). Overexpression of XIAP signiﬁcantly reduced cell death
by the chemotherapeutic agent etoposide (P < 0.05). The com-
pound SG1 per se only slightly increased the number of apoptotic
cells, whereas SG1 signiﬁcantly increased apoptosis in etoposide-
treated, XIAP-overexpressing cells (P < 0.05). In contrast, no sensi-
tizing effect can be observed for SG3 (Fig. S1). The sensitizing effect
of SG1 to etoposide-induced apoptosis in Molt3/XIAP cells is dose-
dependent, as the number of AnnexinV positive cells rises with
increasing concentrations of SG1 (Fig. 4C).
3.8. Compound SG1 does not induce cIAP1 degradation
To test whether SG1 interferes also with the function of other
IAPs such as cIAP1, we treated the cIAP1-inhibitor sensitive cell
lines OVCAR-4 and HTB-77 with SG1 and used as a positive con-
trol embelin. The cell lines OVCAR-4 and HTB-77 undergo sponta-
neous apoptosis when these cells are treated with an inhibitor
speciﬁc for cIAP1 [62]. Inhibitor treatment should also cause rapid
depletion of cIAP1 protein levels [62]. As shown in Fig. 5A treat-
ment of HTB-77 cells with 6.8 lM SG1 and OVCAR-4 cells with
17 lM SG1 does not elevate apoptosis. In a next step we com-
pared the effect of SG1 on cIAP1 and cIAP2 protein expression
with the smac mimetics LCL-161 (Novartis) and TL32711 (Birina-
pant, Tetralogic) (Fig. 5B). The same results are achieved with the
XIAP-inhibitor embelin (Fig. S2). This suggests that SG1, like
embelin, neither inhibits cIAP1 / cIAP2 function nor induces the
degradation of these IAPs, which supports the notion that SG1
predominantly targets XIAP and neutralizes its function in malig-
nant cells.A 
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Fig. 5. Proof of speciﬁcity of SG1 for XIAP in the cIAP1-inhibitor sensitive cell lines OVCA
incubated with SG1 (8.5 lM) for 48 h and then subjected to FACS analysis of PI-stained nu
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levels. The smac mimetics LCL-161 (L) and TL32711 (TL) which both neutralize cIAP1/23.9. Sensitization of neuroblastoma cells to chemotherapy-induced
apoptosis by SG1
To determine whether SG1 is able to sensitize different neuro-
blastoma cell lines with naturally high XIAP levels (Fig. S3) to eto-
poside-induced apoptosis we treated SH-EP, IMR-32 and NxS2 cells
with 10 lM SG1 and with different concentrations of etoposide
(250 lM, 750 lM, 1270 lM). In all three cell lines treatment with
SG1 induces apoptosis as measured by PI-FACS-analyses (Fig. 6A–
C). IMR-32 cells are only partially sensitized by SG1, whereas SH-
EP and NxS2 cell lines were sensitized to cell death by SG1 in com-
bination with all doses of etoposide. The murine neuroblastoma
cell line NxS2 was most sensitive to SG1-treatment (P < 0.01).
The chemosensitizing effect of SG1 in these cell lines can be
explained by their elevated XIAP-expression compared to the leu-
kemia cell line Molt4 which has signiﬁcant lower XIAP levels
(Fig. S3) and does not show increased apoptosis levels after treat-
ment with SG1 (data not shown).
4. Discussion
Much effort has been invested into the development of XIAP-
inhibitors due to the fact that XIAP is a central inhibitor of inducer-
and executor-caspases and is overexpressed in many different
types of tumors [15–20]. This has led to the idea that XIAP is a
promising therapeutic target for personalized cancer medicine.
Most inhibitors, some of them are already in preclinical phase I
and phase II trials (TL32711, Tetralogic Pharmaceuticals; LCL161,
Novartis; AEG35156, Aegra Therapeutics) [29], are peptidic struc-
tures derived from the processed N-terminus of the cellular
XIAP-inhibitor SMAC/DIABLO that is released from mitochondria
upon cell death induction.
In this study we identiﬁed the natural substances sanggenon G
(SG1) and kuwanon L (SG3) as novel, non-peptidic, small-molecu-
lar weight inhibitors of XIAP. The compound SG1 and the structur-
ally-related compound SG3 were identiﬁed as components of an
extract from Morus alba root bark (MAC) in a FP-based screeningcIAP1
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Fig. 6. Induction of apoptosis by SG1 in neuroblastoma cell lines. (A–C) IMR-32,
NxS2 and SH-EP cells were treated with 10 lM SG1 and 250, 750 and 1270 nM
etoposide. Apoptosis was determined by ﬂow cytometry of PI stained nuclei after
48 h. Shown are means ± s.e.m. of three independent experiments. For statistical
analysis ANOVA with post hoc Bonferroni-analysis was used. A 2-tailed P value
60.05 was considered as signiﬁcant.
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proto-oncogene XIAP (Fig. 1A). As shown by FP-analyses and dock-
ing studies SG1 binds speciﬁcally to the BIR3 domain of XIAP
in vitro (Fig. 1C). The binding afﬁnity of this natural compound to
XIAP was determined to be 34.26 lM at our assay conditions. This
value is in the upper range of active substances but has to be seen
in the context of the XIAP-inhibitor embelin that was used as a ref-
erence compound. For embelin the Ki-value was reported to be
0.4 lM [7]. In our experimental setting we determined the Ki-value
of embelin to be 22.25 lM. These differences to other assay sys-
tems are most likely due to different experimental conditions,
mainly inﬂuenced by temperature, the concentration of the FAM-
labeled ARPF-peptide and recombinant XIAP-BIR3 protein as well
as differences in the sequence and position of the His-tag on the
BIR3-protein which is located C-terminal in our case. Whereas Nik-
olovska-Coleska et al. expressed a recombinant, N-terminal His-
tagged XIAP-BIR3 consisting of the sequence Gly241-His356 [51],
the protein used in our experiments was slightly larger (Phe238-
Glu359), which may also affect binding properties. These differ-
ences are also reﬂected by the Kd-value between BIR3 protein
and the ARPF-FAM-peptide that we measured. In our setting the
Kd-value was 145 nM. In the literature this value varies between20 nM, [60] 38 nM, [51] and 77.6 nM [51]. To classify the XIAP-
inhibiting potency of SG1, we referenced the measured Ki-value
to the Ki-value of the control substance embelin, which suggests
that SG1 binds with a similar afﬁnity to XIAP-BIR3 as embelin.
Importantly, PCA-analyses (Fig. 2B) that directly assess protein–
protein interaction in living cells revealed a signiﬁcant reduction
of the bioluminescence signal to 56% by as low as 2.9 lM SG1. This
signiﬁcantly increased in vivo effect might reﬂect the lower afﬁnity
of the AVPI-peptide to XIAP-BIR3 and is possibly due to effective
import into cells or accumulation in the cytoplasm. It clearly dem-
onstrates that the in vivo efﬁcacy of SG1 to dissociate XIAP-BIR3/
AVPI complexes is much higher than the in vitromeasured binding
efﬁciency. The effective concentration of SG1 in this assay is the
same as for embelin (3.4 lM) suggesting that SG1 has a similar bio-
logical activity.
By use of the PCA assay we further showed that SG1 binds to
XIAP-BIR3 protein in vivo and it competes for the same binding site
as SMAC/DIABLO in living cells. This in vivo binding is a crucial fea-
ture for a potential use of SG1 as a drug candidate because it
already demonstrates that the compound efﬁciently enters the
cytoplasm of the cell and directly interferes with XIAP function.
This is a main advantage of SG1 compared to other compounds
especially the peptide-based ones that are limited in cell perme-
ability and therefore have to be coupled to carrier peptides [63].
In contrast to SG1, the compound SG3 did not show a signiﬁcant
effect in the PCA-sensor (Fig. 2B) and also did not act as a chemo-
sensitizer in XIAP-overexpressing cells (Fig. S1), suggesting that
despite the structural similarity and in vitro activity, compound
SG3 does not enter cells efﬁciently. This is most probably due to
the missing isoprenyl group in contrast to SG1, thus losing the
mandatory hydrophobicity. Intriguingly, further Diels–Alder
adducts isolated from this herbal remedy, namely compounds
SG2, SG4, and SG6 did not show an activity in our in vitro assay.
Non Diels–Alder adducts, i.e. moracin O and P (SG5) belonging to
the chemical class of benzofurans and sanggenol A (SG7), a simple
ﬂavanone with a geranyl moiety in position 3’, neither contribute
to the bioactivity of MAC. These results are in line with the in silico
docking studies revealing that no docking poses exist that match
the 3D-pharmacophore model. Although the chemical diversity
within the investigated Diels–Alder adducts and their sample
number do not allow an in depth structure activity relationship,
it is obvious that the inactive members of this compound class
share a common chemical feature, namely an additional dihydrofu-
ran by cyclization in position 2, 3, 2’ of the ﬂavonoid scaffold form-
ing a rigid condensed four ring system (Fig. 1B). Accordingly, we
hypothesize that the structural features of the ﬂavano-chalcon
moieties which are linked via a cyclohexene-ring system by
Diels–Alder addition need a maintained ﬂexibility of the phenyl
group (ring B) in the ﬂavonoid scaffold to act as ligands of the
XIAP-BIR3 domain. This is only given in compounds SG1 and
SG3. Further, a sufﬁcient hydrophobicity as given by the additional
isoprenyl group in compound SG1 seems to be mandatory for cell
permeability.
A second evidence for the high potency of SG1 is that treatment
of the XIAP-overexpressing cell line Molt3/XIAP with 14.4 lM SG1
synergizes with etoposide to inhibit cell growth and to induce
apoptosis as demonstrated by PI-FACS and AnnexinV staining
(Fig. 4A-B). This dose dependent effect in a range from 8.2 to
14.4 lM (Fig. 4C) suggests a similar biological activity as the
broadly used XIAP inhibitor LBW242 (10 lM) [11,64] which is
already in clinical trial phase I [29] and was used in a number of
different experimental studies such as to enhance vincristine-
induced apoptosis in NxS2 murine neuroblastoma cells [11].
This sensitizing effect was observed not only in the XIAP-over-
expressing leukemia cell line Molt3/XIAP but also in different neu-
roblastoma cell lines endogenously expressing high XIAP levels
670 M.A. Seiter et al. / FEBS Open Bio 4 (2014) 659–671(Fig. S3). Treatment of the neuroblastoma cell lines SH-EP, IMR-32
and NxS2 with SG1 results in a signiﬁcant induction of apoptosis as
measured by PI-FACS-analyses, which is very promising for future
therapeutical use of SG1 (Fig. 6A–C). The combined data suggest
that SG1 overcomes the death-protective effect of XIAP and
restores sensitivity of cells to etoposide-induced apoptosis.
To further investigate the effects of SG1 in detail we analyzed
activation of caspase-3, -8 and -9 (Fig. 3B–D). The inhibitory effect
of XIAP overexpression on the activation of caspase-3 and caspase-
8 in etoposide treated cells was clearly demonstrated by a signiﬁ-
cantly reduced presence of cleavage products in the immunoblot
(Fig. 3B–D). This suggests that caspase-8 and caspase-3 cleavage
occurs downstream of outer mitochondrial membrane permeabili-
zation and caspase-9 activation in these cells and is also inhibited
by XIAP-overexpression. Caspase-3 also activates caspase-9 in an
amplifying feedback loop [65]. As XIAP binds both, caspase-9 and
caspase-3 via its BIR3 and BIR2 domains, respectively, high XIAP
expression interferes also with this processing of caspase-9 by cas-
pase-3 as it was observed in the immunoblot analysis. XIAP associ-
ates with the active, proteolytically processed caspase-9/APAF1
holoenzyme [10,65] and prevents it from activating downstream
caspases like caspase-3 and -7. In Molt3/Ctr cells etoposide treat-
ment mainly triggers the mitochondrial death pathway resulting
in caspase-9 activation and a subsequent increase of partly-pro-
cessed caspase-9 that in turn is sequestered by elevated XIAP-lev-
els in Molt3/XIAP cells. Therefore, increased amounts of processed
caspase-9 in complex with XIAP can be detected during etoposide
treatment as it is also demonstrated in Fig 3E. The observation that
SG1 did not reduce basal caspase-9/XIAP-interaction might be
explained by the fact that we adjusted SG1 concentrations to a
level that per se only partially reduces long term survival (Fig4 A)
and only slightly increases apoptotic cell death (Fig 4B).
Neutralization of XIAP might also facilitate cell death induced
by other death triggers such as death ligands as previously demon-
strated for TRAIL-induced cell death in leukemia cells [30]. Apopto-
sis sensitization by SG1 partially compensated XIAP-mediated
inhibition, which was also reﬂected by increased caspase activa-
tion: treatment with SG1 leads to enhanced caspase activation of
caspases-9, -8 and -3 in Molt3/XIAP cells. Additionally, SG1 treat-
ment releases caspase-9 from inhibition by XIAP by competing
with caspase-9 for the same binding site on XIAP. As shown by
co-immunoprecipitation, treatment with SG1 displaces caspase-9
from XIAP. Taken together these results indicate that SG1 acts as
a chemosensitizer in drug-resistant XIAP-overexpressing cancer
cells.
To further elucidate the speciﬁcity of SG1 we tested whether it
would induce apoptosis spontaneously in the cell lines HTB-77 and
OVCAR-4. These cells have been shown to undergo apoptosis after
addition of a cIAP1 inhibitor [62]. However, treatment with SG1
does not lead to spontaneous apoptosis induction and no sponta-
neous degradation of cIAP1 was detected by immunoblotting con-
trasting to the smac mimetics LCL-161 and TL32711 (Fig. 5A + B).
We conclude from these results that SG1 speciﬁcally targets XIAP.
The combined data indicate that sanggenon G (SG1) is a promis-
ing new XIAP inhibitor of natural origin that acts as a chemosensitiz-
er in XIAP-expressing cancer cells by neutralizing the pro-survival
function of XIAP via binding to its BIR3 domain. The chemical
structure of SG1 might serve as a starting point to develop a new
class of improved, non-peptidic XIAP inhibitors that may be used
in combination therapy to reduce doses of chemotherapeutic drugs
and therapy side effects.
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